Table of Contents
A new open-label trial published in June 2026 offers some of the most encouraging data yet on psilocybin-assisted therapy veterans living with treatment-resistant depression. According to the study, a single oral dose of 25 milligrams of psilocybin was associated with a 59 percent reduction in anxiety scores at three weeks, and those improvements in anxiety, quality of life, and daily functioning were sustained at the twelve-month follow-up mark.
Who Was in the Study and What Happened
The participants were veterans who had not responded adequately to prior depression treatments, a clinical profile researchers refer to as treatment-resistant depression, or TRD. The trial was open-label, meaning participants knew they were receiving psilocybin rather than a placebo. Each participant received a single 25mg psilocybin dose administered in a structured therapeutic context. Researchers then tracked outcomes at multiple time points, extending all the way to twelve months post-session.
The headline finding is the anxiety reduction: a 59 percent decrease measured at the three-week mark. Alongside that, the study reported meaningful gains in quality of life and overall functioning, with those improvements persisting through the full year of follow-up. For a population frequently described as among the hardest to reach with conventional pharmacotherapy, that duration of effect is notable.
What the Data Can and Cannot Tell Us About Psilocybin Efficacy
It is important to hold this study’s design in mind when reading its results. Open-label trials, by their nature, carry the possibility of expectancy effects: participants who know they have received an active treatment may report improvements that are partly shaped by that knowledge. There was no placebo control group here for direct comparison. The researchers themselves are working within that honest limitation.
This means the findings are best understood as hypothesis-generating rather than definitive proof of efficacy. They add a meaningful data point to a growing body of work on psilocybin therapy for depression, and they do so in a specific, underserved population whose mental health needs have historically gone unmet. They do not, on their own, establish that psilocybin caused these outcomes independent of other therapeutic factors.
Why Veterans with Treatment-Resistant Depression Are a Critical Population
Veterans carry a disproportionate burden of depression, post-traumatic stress, and suicidality. Many have cycled through available treatments without lasting relief. Research focused specifically on this population is both ethically important and scientifically valuable, because the context of military service, trauma, and its aftermath may shape how psychological distress presents and how treatments land.
The twelve-month follow-up window is also worth noting. Much of the existing psilocybin research has focused on shorter-term outcomes. Data suggesting that a single facilitated psilocybin session can produce measurable improvements in functioning and quality of life across a full year, even in a preliminary open-label format, points toward questions worth investigating in more rigorously controlled trials.
Does a Single Psilocybin Dose Improve Long-Term Functioning?
According to this trial, yes: a single 25mg psilocybin dose was associated with sustained improvements in daily functioning and quality of life at twelve months in veterans with treatment-resistant depression. That is a longer follow-up window than most existing psilocybin studies have used, which makes the duration of these reported gains one of the more significant aspects of this data set, even accounting for the open-label design.
How Does Psilocybin-Assisted Therapy Work in a Clinical Setting?
In this trial, psilocybin was not administered in isolation. Each participant received the 25mg dose within a structured therapeutic context, meaning trained support was present before, during, and after the session. The study does not establish which element, the psilocybin itself or the surrounding therapeutic framework, drove the observed outcomes. That question remains one of the central unknowns in the broader field of psychedelic-assisted therapy for depression.
One Door, Left Open for a Year
What strikes us here is not the percentage point, striking as it is. It is the duration. Twelve months after a single session, veterans who had not found relief through conventional medicine were still reporting better functioning, better quality of life, less anxiety. Something opened and, for many, it stayed open.
We believe psilocybin, when held in a careful and intentional container, can initiate a process of integration that continues long after the session ends. This study does not prove that, but it is consistent with it. The healing work does not happen in the hours of the experience alone. It ripples forward into the ordinary days that follow.
For those who have served and who carry wounds that medication alone has not reached, this research represents a quiet and serious kind of hope. Not a cure proclaimed, but a door worth opening, with the right support on the other side.
If this research resonates with you, whether you are a veteran, a clinician, a loved one, or simply someone who has known the weight of treatment-resistant suffering, we welcome you into this ongoing conversation. The Integration station of our Golden Path is a place to sit with what emerges after an experience, to give it meaning, and to carry it gently into daily life. You are not alone in that work.
May love guide the hearts of all beings.
